Skip to main content
SpringerLink
Log in

Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer

Profile Report

  • Adis Profile Report
  • Published:
BioDrugs Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I

References

  1. Parkin DM, Bray F, Ferlay J. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2): 74–108

    Article  PubMed  Google Scholar 

  2. Arpino G, Wiechmann L, Osborne CK, et al. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008 Apr; 29(2): 217–33

    Article  PubMed  CAS  Google Scholar 

  3. Roskoski Jr R. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 2004 Jun 18; 319(1): 1–11

    Article  PubMed  CAS  Google Scholar 

  4. Brenton JD, Carey LA, Ahmed AA, et al. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol 2005 Oct 10; 23(29): 7350–60

    Article  PubMed  CAS  Google Scholar 

  5. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000 Aug 17; 406(6797): 747–52

    Article  PubMed  CAS  Google Scholar 

  6. Cortes J, Baselga J. How to treat hormone receptor-positive, human epidermal growth factor receptor 2-amplified breast cancer. J Clin Oncol 2009 Nov 20; 27(33): 5492–4

    Article  PubMed  Google Scholar 

  7. Frampton JE. Lapatinib: a review of its use in the treatment of HER2-over-expressing, trastuzumab-refractory, advanced or metastatic breast cancer. Drugs 2009 Oct 22; 69(15): 2125–48

    Article  PubMed  CAS  Google Scholar 

  8. Curran MP. Lapatinib: in postmenopausal women with hormone receptor-positive, HER2-positive metastatic breast cancer. Drugs 2010; 70(11): 1411–22

    Article  PubMed  CAS  Google Scholar 

  9. TYKERB (lapatinib tablets): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009

  10. European Medicines Agency. Tyverb® 250mg tablets (lapatinib) [online]. Available from URL: http://www.ema.europa.eu [Accessed 2010 Jun 15]

  11. Schwarzberg LS, Franco SX, Florance A, et al. Lapatinib plus letrozole as first-line therapy for HER-2+ hormone receptor-positive metastatic breast cancer. Oncologist 2010; 15(2): 122–9

    Article  PubMed  CAS  Google Scholar 

  12. Johnston S, Pippen Jr J, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009; 27(33): 5538–46

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments and Disclosures

The full text article[8] from which this profile report was derived was reviewed by: Q. Chu, Medical Oncology, Cross Cancer Institute, Edmonton, Alberta, Canada; E.A. Perez, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, Florida, USA.

The manufacturer of the agent under review was offered an opportunity to comment on the original article[8] during the peer review process; changes resulting from comments received were made on the basis of scientific and editorial merit. The preparation of the original article and this profile report was not supported by any external funding.

Author information

Authors and Affiliations

  1. Adis, a Wolters Kluwer Business, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754, Auckland, New Zealand

    Monique P. Curran

Authors
  1. Monique P. Curran
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Monique P. Curran.

Additional information

Adapted and reproduced from the original article published in Drugs 2010; 70 (11): 1411–1422

Rights and permissions

Reprints and permissions

About this article

Cite this article

Curran, M.P. Lapatinib in Postmenopausal Women with Hormone Receptor-Positive, HER2-Positive Metastatic Breast Cancer . BioDrugs 25, 53–54 (2011). https://doi.org/10.2165/11207270-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11207270-000000000-00000

Keywords

Search

Navigation